Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy
Status:
Active, not recruiting
Sponsors
Tabula Rasa HealthCare
Abstract:
This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in elderly people enrolled in PACE organizations. Our clinical tool would enable to identify potential multi-drug interactions and potentially reduce the risk of adverse drug events (ADE) developing in elderly patients infected with COVID-19.
Description:
Certain investigational agents have been described in observational series or are being used anecdotally based on in vitro or extrapolated evidence. It is important to acknowledge that there are no controlled data supporting the use of any of these agents, and their efficacy for COVID-19 is unknown. FDA-approved drugs such as chloroquine/hydroxychloroquine, lopinavir/ritonavir, monoclonal IL-6 antibodies, JAK inhibitors, thalidomide and the new investigational drug, remdesivir have been proposed for repurposing to fight COVID-19 and its complications.
A medication risk stratification strategy will be used to simulate the impacts of different potential repurposed drugs for COVID-19 on the Medication Risk Score (MRS) which is used as a predictive tool for ADEs. A retrospective study will be conducted using de-identified drug claims data of elderly patients with polypharmacy.
Patients meeting all the following criteria will be included:
1. Patient enrolled in a PACE organization during the implementation period;
2. PACE organization contractually receiving pharmacy services from CareKinesis;
Exclusion Criteria
a) No drug claims data available for the period of 2019-2020
This retrospective cohort will utilize 178,867 drug claims from approximately 12,123 patients enrolled in PACE. MRS will be calculated using the last available 3-month period of drug claims in 2019. The data elements required for the calculation of the full set of risk scores are: prescribed drugs, dose, age, gender. Medication risk stratification using 5 factors will be performed to obtain the MRS. Various repurposed drugs (drugs associated with the highest probability or efficacy or shown interest as per their inclusion in current clinical trials will be prioritized) will be added to the patient drug regimen except for the patients that are currently taking the repurposed drug. A new MRS will be generated for all stratified patients.
Condition or disease:COVID
Drug Effect
Drug Interaction
Adverse Drug Event
Intervention/treatment:
Other: Program of All-Inclusive Care for the Elderly
Phase:-
Study design:
Study Type:Observational
Observational Model:Cohort
Time Perspective:Retrospective
Arm group:
ArmIntervention/treatment
Program of All-Inclusive Care for the Elderly
The Program of All-Inclusive Care for the Elderly (PACE) provides comprehensive medical and supportive services for community-dwelling persons, mostly older adults (>55 years), as an alternative to institutionalization. Medical services are provided by an interdisciplinary team of healthcare professionals, Tabula Rasa HealthCare being the pharmacy care provider for several PACE organizations.
Other: Program of All-Inclusive Care for the Elderly
This study is a simulation of adding repurposed drugs for COVID-19. We are using drug claims, and will not intervene with patient care.
Eligibility Criteria:
Ages Eligible for Study:55 Years to 55 Years
Sexes Eligible for Study:All
Sampling method:Non-Probability Sample
Accepts Healthy Volunteers:Yes
Criteria:

Inclusion Criteria:

- Patient enrolled in a PACE organization during the implementation period;

- PACE organization contractually receiving pharmacy services from CareKinesis;

Exclusion Criteria:

- No drug claims data available for the period of 2019-2020

Outcome:
Primary Outcome Measures
1. To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen. [Three months]
Quantitative
2. To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen. [Three months]
Quantitative
3. To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19. [Three months]
Quantitative
4. To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score. [3 months]
Quantitative
Secondary Outcome Measures
1. To investigate the effects of various covariables on the Medication Risk Score in the presence of repurposed drugs for COVID-19. [6 months]
Qualitative
2. To explore the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used. [1 year]
Qualitative
Relations:
Publications
(5)
Diseases
(1)
Drugs
(5)
Chemicals
(1)
Processes
(1)
Affiliates
(2)
Discussion board
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.